Incidence of Alpha-1
Who gets Alpha-1?
Alpha1 antitrypsin deficiency is more common than many people realize:
- An estimated 25 million people in the US are at increased risk for Alpha-15
- Not all genetically predisposed individuals will develop clinically significant
symptoms. Your doctor can conduct tests to determine if you have Alpha-1
Alpha-1 affects a variety of racial and ethnic groups around the world5,6
- Whites worldwide
- Africans
- Middle Eastern people
- Central, far east, and southeastern Asians
- Hispanic and Black Americans
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.